Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 251 - 300 of 1864 results
- Biodistribution and localization of iodine-131-labeled metuximab in patients with hepatocellular carcinoma.
- Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs.
- Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
- A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells.
- Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter.
- Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model.
- Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.
- The role of interleukin 1 in growth and metastasis of human cancer xenografts.
- Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.
- Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer.
- Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.
- Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates.
- Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
- Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies.
- Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice.
- Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
- Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein.
- Effects of rate, volume, and dose of intratumoral infusion on virus dissemination in local gene delivery.
- Restriction of adenoviral replication to the transcriptional intersection of two different promoters for colorectal and pancreatic cancer treatment.
- Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.
- Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma.
- The role of human papillomavirus in squamous carcinoma of the head and neck.
- Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma.
- Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.
- Inflammatory chemokines in cancer growth and progression.
- Cancer CXC chemokine networks and tumour angiogenesis.
- Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.
- Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA.
- Gene therapy of ovarian cancer with IFN-alpha-producing fibroblasts: comparison of constitutive and inducible vectors.
- A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.
- Immunotherapy for prostate cancer.
- Development and characterization of interleukin-18-loaded biodegradable microspheres.
- Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma.
- Synergistic antitumor effects of immune cell-viral biotherapy.
- Characterization of the recombinant adenovirus vector AdYB-1: implications for oncolytic vector development.
- G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
- Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth.
- Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
- Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine.
- Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).
- TLR3 can directly trigger apoptosis in human cancer cells.
- Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin.
- Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.
- Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2.
- Development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling.
- A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis.
- CCL19 reduces tumour burden in a model of advanced lung cancer.
- Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma.
- B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.
- Interleukin-2 gene-encoded stromal cells inhibit the growth of metastatic cholangiocarcinomas.